Virpax Pharmaceuticals, Inc. (VRPX)

NASDAQ: VRPX · IEX Real-Time Price · USD
2.230
+0.040 (1.83%)
At close: May 2, 2024, 4:00 PM
2.210
-0.020 (-0.90%)
After-hours: May 3, 2024, 5:20 PM EDT
1.83%
Market Cap 2.62M
Revenue (ttm) n/a
Net Income (ttm) -15.19M
Shares Out 1.17M
EPS (ttm) -12.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,165
Open 2.300
Previous Close 2.190
Day's Range 2.230 - 2.660
52-Week Range 2.105 - 11.770
Beta 1.38
Analysts n/a
Price Target n/a
Earnings Date May 14, 2024

About VRPX

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal s... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 17, 2021
Employees 7
Stock Exchange NASDAQ
Ticker Symbol VRPX
Full Company Profile

Financial Performance

Financial Statements

News

Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Results of MTD Study for Probudur. Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief.

5 days ago - Business Wire

Virpax Pharmaceuticals Reports 2023 Year-End Results

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2023 Year-End Results.

5 weeks ago - Business Wire

Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price.

2 months ago - Business Wire

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

2 months ago - Business Wire

Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Preliminary Results of Probudur™ Pilot Study with the U.S. Army Institute of Surgical Research.

3 months ago - Business Wire

Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Results of Special Shareholders Meeting.

4 months ago - Business Wire

Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing.

6 months ago - Business Wire

Virpax Pharmaceuticals Announces Leadership Transition

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Leadership Transition.

6 months ago - Business Wire

Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Reports 2023 Third Quarter Results and Recent Developments.

6 months ago - Business Wire

Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review.

6 months ago - Business Wire

Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Extension of CRADA with the U.S. Army Institute of Surgical Research.

7 months ago - Business Wire

Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Results of Probudur™ Dose Escalation Studies.

7 months ago - Business Wire

Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at the LD Micro Main Event XVI.

7 months ago - Business Wire

Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses

LAVAL, Québec--(BUSINESS WIRE)-- #Altasciences--Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive...

8 months ago - Business Wire

Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces the Formation of Novvae™ Pharmaceuticals.

8 months ago - Business Wire

Virpax Pharmaceuticals Updates on Litigation

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-...

Other symbols: SCLX
8 months ago - Business Wire

Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at H.C. Wainwright 25th Annual Global Investment Conference.

8 months ago - Business Wire

Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2023 Second Quarter Results and Recent Developments.

9 months ago - Business Wire

Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-...

9 months ago - Business Wire

Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Ring NASDAQ Closing Bell on July 24, 2023.

10 months ago - Business Wire

Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2023 First Quarter Results and Recent Developments.

1 year ago - Business Wire

Nanomerics Announces Ocular Molecular Envelope Technology (MET) Patent Granted in Canada

LONDON, UK / ACCESSWIRE / April 13, 2023 / Nanomerics Ltd., a private speciality pharmaceutical company today announced that the Company had been granted patent protection in Canada for the ocular use...

1 year ago - Accesswire

Virpax Reports on Progress of Envelta™

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-...

1 year ago - Business Wire

Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-...

1 year ago - Business Wire

Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China

BERWYN, Pa.--(BUSINESS WIRE)-- Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumat...

1 year ago - Business Wire